Description
General description
A potent, cell-permeable inhibitor of protein kinase G Iα, Iβ, and type II. A combination of the protein kinase inhibitor Rp-cGMPS and the widely used cGMP analog, 8-pCPT-cGMP. Significantly more lipophilic and membrane-permeant than Rp-cGMPS and Rp-8-Br-cGMPS. Resistant to hydrolysis by mammalian cyclic nucleotide dependent phosphodiesterases. Note: 1 µmol = 0.61 mg.
A potent, cell-permeable, and metabolically-stable inhibitor of protein kinase G Iα, Iβ, and type II. Significantly more lipophilic and membrane-permeable than Rp-cGMPS or Rp-8-Br-cGMPS (Cat. No. 370674). Note: 1 µmol = 0.61 mg.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PKG1α
Product does not compete with ATP.
Reversible: no
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Abd Alla, S., et al. 1996. Eur. J. Biochem.241, 498.
Lee, S.J., et al. 1996. Dev. Biol.180, 324.
Van Uffelen, B.E., et al. 1996. J. Leukoc. Biol.60, 94.
Willmott, N., et al. 1996. J. Biol. Chem.271, 3699.
Butt, E., et al. 1994. Eur. J. Pharmacol. 269, 265.
Legal Information
Sold under license of U.S. Patent 5,625,056, Patents DE 3,802,865.4, and DE 4,217,679 issued to BIOLOG LSI.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
